AACCE Investments
ScreenerStocksIndicesPicksETFsBlogPricing

© 2026 ACCE Investments. All rights reserved.

ACCE Investments - Institutional-grade stock research for retail investors | BetaList
IndicesStocksETFsScreenerBlogGlossaryCompareMarket dataAdvisors
TermsPrivacyCookiesDisclaimerLegal noticeProfessional termsAboutContact
TDOC
ACCE-researched

Teladoc Health Inc. Common Stock (TDOC) fair value

Healthcare · Health Information Services · NYSE · United States
$6.34+0.32%
Market cap $1.1BNext earnings 2026-10-28Updated Oct 18, 2026
Add earnings to calendarGoogle
Our verdict
Trades 14% below our fair value
Price
$6.34
Model fair valueConfidence: medium
$7.41
Only one of our models could value this stock with confidence, so use it as a guide.
Not used by alerts or posts.
Valued as a growth company: Discounted cash flow and EV/EBITDA comparison.
ACCE opinionTeladoc Health Inc. Common Stock (TDOC)
Fair value (2 models)
Not available
ACCE price target
$6.00
Rating
Not rated
Horizon
12 months
ACCE price target published on 29 Sept 2026, 00:00 CEST.
Price used: $6.34 at the close on 23 Oct 2026, 22:00 CEST.
Models: Discounted cash flow and EV/EBITDA comparison.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Full methodology
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
38
out of 100
Analysts
26% buy
23 covering
P/E
0.0x
forward 303.0x
1-year return
-26.3%
Dividend yield
0.00%

Teladoc Health Inc. Common Stock in four questions

Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
OverviewAsk ACCEValuationQualityAnalystsSmart MoneyCompareNews and Record

Overview

ACCE thesis

Teladoc Health provides virtual care, including telehealth visits, chronic condition programmes and mental health services through BetterHelp. Its employer and health plan relationships give it distribution. Growth depends on stabilising BetterHelp and chronic care enrolment. Revenue fell 4.0% with a 69.0% gross margin, but the operating margin is -5.7% and the forward multiple is 303.0x.

AI-assisted·How I use AIWritten Oct 14, 2026
⚠ Investor warnings · 4 flagsAI-assisted·How I use AI
  • high
    Revenue decline with margin pressure
    Revenue down 4.0% YoY and 1.1% QoQ. Operating margin negative at -5.7% and net margin -7.1%. Company not yet profitable despite high gross margin of 69%.
  • high
    ACCE score collapse
    Score fell 10 points in 90 days (47 to 37). Quality subscore 43 and Momentum subscore 39 both weak. Fair value $6.00 vs current price $5.77 offers minimal margin of safety.
  • moderate
    Elevated short interest with insider selling
    Short interest 16.7% of float. Insiders sold $0.38M in last 10 disclosures with zero buys. Negative signal on conviction at current levels.
  • moderate
    Negative return on equity
    ROE -13.0% indicates the business is destroying shareholder value. Despite $285M FCF, underlying profitability remains challenged.

AI research notes

AI-assisted·How I use AIWritten Oct 11, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
  • Free cash flow yield of 27.2% suggests the market has priced in excessive pessimism about the business.
  • Analyst consensus price target of $7.59 implies 31.5% upside from current levels of $5.77.
  • Five-year revenue growth averaged 18.3% annually, showing the core business model has worked historically.
Why it could disappoint
  • Forward P/E of 303.0x is indefensible even for a growth stock, given revenue declined 4.0% year over year.
  • Company is unprofitable with negative 7.1% net margin and negative 13.0% return on equity.
  • Only 26% of analysts rate the stock Buy or Strong Buy, and share count dilution of 3.3% last year erodes existing holders.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.

Next results

Oct 28, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Ask ACCE

Valuation

INVESTOR
Where TDOC's valuation models land
Price
$6.34
Model fair valueConfidence: medium
$7.41
Model
Fair value
Upside
Discounted cash flow
EV/EBITDA comparison
Create a free account: 5 full stock pages a month, no card.

See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.

  • +A plain reason under every score
  • +Conviction breakdown and growth / value / quality / momentum scores
  • +Score history: how each score moved over time

Analysts

Wall Street consensus

Bearish26% buy · 23 covering analysts
● Strong buy 5● Buy 1● Hold 17● Sell 0● Strong sell 0
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO

In one line

Trades are only made public after a delay. We show the delay so you know how old the news is.

Company insiders
No trades filed
Last 90 days
Congress
No trades filed
Last 180 days
Average delay
No trades filed
From trade to public filing
Do politicians beat the market? Our backtest →
Smart money tracking PRO FEATURE

Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Every insider and Congress trade, with how late it was disclosed
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

News and Record

Press releases mentioning this company

Recent performance

1 week
+11.8%
1 month
+3.4%
3 months
-27.7%
6 months
+10.3%
YTD
-9.4%
1 year
-26.3%

SEC filings

Recommendation history, last 12 months

DateTypeNewPreviousPrice
15 Oct 2026, 00:00 CESTFair value$14.19$11.44$6.00
29 Sept 2026, 00:00 CESTACCE price target$6.00first publication$5.89
19 Aug 2026, 00:00 CESTFair value$11.44first publication$6.54

This analysis is not personalised investment advice and does not take your situation, objectives or risk tolerance into account. ACCE Investments is not an authorised investment firm.

Investing in shares carries a risk of losing capital. The value of an investment can go down as well as up.

Valuation horizon: 12 months from the publication date.

Conflicts of interest. ACCE Investments is operated by Adrien Chantreuil, who may hold personal positions in the securities analysed. Positions are declared on each security. ACCE receives no payment from the companies analysed or from any intermediary for this analysis.

Get the full TDOC page, free

Every model, the scenarios, fair value history, AI notes and the four questions. 5 full stock pages every month on the free plan, no card.

Free accounts get 5 full stock pages a month, including the full page.

Snapshot

Growth7Value57Quality43Momentum45Total38
Valuation
Trailing P/E
0.0x
Forward P/E
303.0x
PEG
no data
P/B
0.88x
EV / Revenue
0.6x
Book value/sh
$7.21
Enterprise value
$1.4B
Profitability
ROE
-13.0%
FCF yield
24.86%
ROIC
-6.8%
Health and risk
Debt / equity
0.75
Dividend yield
0.00%
Beta
2.14

Price

-33.0% · 1Y

Ask anything about TDOC

Answered from Teladoc Health Inc. Common Stock fundamentals + recent valuations. Every number shows its source and date.

This stock Peer Peer median weaker → stronger
P/Ebetter than 100% of peers
low 0.0x0.0xhigh 79.1x
ROEbetter than 0% of peers
low -13%-13%high 6%
Div yieldbetter than 83% of peers
low 0.0%0.0%high 0.4%

Peers

Prices Oct 23, 2026
CompanyPriceFair valuevs fair valueP/EROEQualityScore
TDOC Teladoc Health Inc. Common Stock$6.34----13.0%4338
OMDA Omada Health Inc. Common Stock$18.95--79.1x1.8%4347
GDRX GoodRx Holdings Inc. Class A Common Stock$3.54$535% below70.8x2.5%5451
HSTM HealthStream Inc. Common Stock$35.16$2171% above46.7x6.0%7171
TALK Talkspace Inc. Common Stock$5.25---0.2%2752
CERT Certara Inc. Common Stock$10.33$822% above--2.2%4744
PHR Phreesia Inc. Common Stock$12.70$1619% below74.7x3.1%5567

Sector report card

Where TDOC ranks against its sector peers on each metric.

Computing percentiles…
  • GlobeNewswire•Oct 14, 2026
    Teladoc Health to Announce Third Quarter 2026 Financial Results
  • GlobeNewswire•Oct 7, 2026
    Teladoc Health Expands Solo Connected Care Platform with AI-Powered Capabilities to Help Hospitals Scale Smarter Care Delivery
  • PR Newswire•Sep 28, 2026
    Evergreen Nephrology Appoints Brian Palo as Chief Financial Officer
8 more press releases · full archive on Investor+.INVESTOR
40 filings
October 2026
Oct 5
Form 4Insider transactionPeriod 2026-10-01
View on SEC →
September 2026
Sep 25
8-KCurrent reportPeriod 2026-09-24
View on SEC →
Sep 14
Form 4Insider transactionPeriod 2026-09-10
View on SEC →
37 more filings + AI summaries on Investor+.INVESTOR